Biotron Ltd (ASX: BIT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Biotron Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$6.75 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
2.41 billion
Earnings per share
-0.002
Dividend per share
N/A
Year To Date Return
-16.67%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Biotron Ltd (ASX: BIT)
Latest News
Share Gainers
Biotron share price rockets 38% on COVID trial results
Healthcare Shares
The Biotron (ASX:BIT) share price just exploded 86% on COVID drug update
Share Gainers
Why Biotron, Fortescue, Ramelius, & Temple & Webster are storming higher
Share Market News
Biotron share price rockets 47% higher on COVID-19 compound testing update
Share Market News
Biotron share price rockets 30% on latest antiviral drug data
Share Market News
Why the Biotron share price has soared 22% higher today
Share Gainers
Why Biotron, Karoon Energy, Pro Medicus, & WiseTech Global are pushing higher
Share Gainers
These ASX shares are fighting the spread of coronavirus
52-Week Highs
Why CSL and these ASX shares just hit 52-week highs
Share Gainers
Biotron share price jumps 70% in two days on coronavirus hopes
Share Gainers
Why Biotron, De Grey Mining, Kathmandu, & Nick Scali are storming higher
Share Market News
ALL ORDINARIES finishes higher Thursday: 8 ASX shares you missed
BIT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Biotron Ltd
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.
BIT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 02 Apr 2026 | $0.00 | $0.00 | 0.00% | 425,223 | $0.00 | $0.00 | $0.00 |
| 31 Mar 2026 | $0.00 | $0.00 | 0.00% | 2,000,000 | $0.00 | $0.00 | $0.00 |
| 30 Mar 2026 | $0.00 | $0.00 | 0.00% | 300,406 | $0.00 | $0.00 | $0.00 |
| 27 Mar 2026 | $0.00 | $0.00 | 0.00% | 57,628 | $0.00 | $0.00 | $0.00 |
| 26 Mar 2026 | $0.00 | $0.00 | 0.00% | 160,000 | $0.00 | $0.00 | $0.00 |
| 25 Mar 2026 | $0.00 | $0.00 | 0.00% | 1,087 | $0.00 | $0.00 | $0.00 |
| 24 Mar 2026 | $0.00 | $0.00 | 0.00% | 907,114 | $0.00 | $0.00 | $0.00 |
| 23 Mar 2026 | $0.00 | $0.00 | 0.00% | 2,462,287 | $0.00 | $0.00 | $0.00 |
| 20 Mar 2026 | $0.00 | $0.00 | 0.00% | 4,100,687 | $0.00 | $0.00 | $0.00 |
| 19 Mar 2026 | $0.00 | $0.00 | 0.00% | 5,672,386 | $0.00 | $0.00 | $0.00 |
| 18 Mar 2026 | $0.00 | $0.00 | 0.00% | 3,130,076 | $0.00 | $0.00 | $0.00 |
| 16 Mar 2026 | $0.00 | $0.00 | 0.00% | 1,442,534 | $0.00 | $0.00 | $0.00 |
| 13 Mar 2026 | $0.00 | $0.00 | 0.00% | 2,494,754 | $0.00 | $0.00 | $0.00 |
| 12 Mar 2026 | $0.00 | $0.00 | 0.00% | 100,684 | $0.00 | $0.00 | $0.00 |
| 11 Mar 2026 | $0.00 | $0.00 | 0.00% | 3,141,182 | $0.00 | $0.00 | $0.00 |
| 10 Mar 2026 | $0.00 | $0.00 | 0.00% | 1,404 | $0.00 | $0.00 | $0.00 |
| 09 Mar 2026 | $0.00 | $0.00 | 0.00% | 13,647 | $0.00 | $0.00 | $0.00 |
| 06 Mar 2026 | $0.00 | $0.00 | 0.00% | 810,237 | $0.00 | $0.00 | $0.00 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 19 Dec 2025 | Robert Thomas | Issued | 2,800,000 | $8,400 |
Rights issue.
|
| 19 Dec 2025 | Robert Thomas | Issued | 1,400,000 | $4,200 |
Rights issue.
|
| 19 Dec 2025 | Michelle Miller | Issued | 1,325,000 | $3,975 |
Rights issue.
|
| 19 Dec 2025 | Michelle Miller | Issued | 1,200,000 | $3,600 |
Rights issue.
|
| 19 Dec 2025 | Michelle Miller | Issued | 1,262,500 | $3,787 |
Rights issue.
|
| 19 Dec 2025 | Michael Medway | Issued | 7,500,000 | $22,500 |
Rights issue.
|
| 19 Dec 2025 | Michael Medway | Issued | 15,000,000 | $45,000 |
Rights issue.
|
| 19 Dec 2025 | Michael Hoy | Issued | 7,478,236 | $22,434 |
Rights issue.
|
| 19 Dec 2025 | Michael Hoy | Issued | 3,739,118 | $11,217 |
Rights issue.
|
| 08 Apr 2025 | Robert Thomas | Issued | 4,200,000 | $12,600 |
Rights issue.
|
| 08 Apr 2025 | Michael Hoy | Issued | 11,217,353 | $33,652 |
Rights issue.
|
| 08 Apr 2025 | Michelle Miller | Issued | 1,987,500 | $5,962 |
Rights issue.
|
| 08 Apr 2025 | Michelle Miller | Issued | 1,800,000 | $5,400 |
Rights issue.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Michael J Hoy | Non-Executive DirectorNon-Executive Chairman | Feb 2000 |
Mr Hoy has more than 30 years of corporate experience in Australia, the United Kingdom, USA and Asia. He is Chairman of Lipotek Pty Limited and a former director of John Fairfax Holdings Limited and FXF Trust.
|
| Dr Michelle Miller | Managing Director | Jun 2002 |
Dr Miller has worked for over 25 years in the bioscience industry, with experience in commercial drug development. Her experience includes several years at Johnson and Johnson developing anti-HIV gene therapeutics through preclinical research to clinical trials. She has finance industry experience from time spent as an Investment Manager with a specialist bioscience venture capital fund.
|
| Dr Paul Alexander Kasian | Non-Executive Director | Dec 2025 |
Dr Kasian has over 30 years of experience in executive and non-executive leadership roles, demonstrating domestic and international in creating and building businesses. He has skills in business management/development, leadership and board level decision making. He is currently Chairman of Diamond Key International. Dr Kasians previous roles include: Executive Chairman at Sedarex Ltd; Executive Chairman at Genetic Technologies Ltd; Non Executive Director (and Chairman of the Audit and Risk Committee) at Atomo Diagnostics Ltd; Chairman at IODM Ltd; Executive Chairman at Zucero Therapeutics Ltd; Chief Investment Officer at HSBC Asset Management Australia.
|
| Mr Michael James Medway | Non-Executive Director | Jul 2025 |
Mr Medway has worked in the accounting industry for over 30 years. He has been a Chartered Accountant for over 30 years, and his background has seen him work across various firms in Sydney and Regional NSW where he provided a range of accounting services to a small to medium enterprises. He is currently a Director of Maas Group Holdings Limited (ASX: MGH) which he was appointed to during its IPO process in 2020.
|
| Mr Graeme Wald | Non-Executive Director | Mar 2026 |
Mr Wald has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch. He has experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He was also founding Chairman of Prota Therapeutics Pty Ltd and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio.
|
| Mr Marcelo Mora | Company Secretary | May 2025 |
-
|
| Marcelo Mora | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Jey Investment Pty Ltd | 42,228,317 | 3.18% |
| Rookharp Capital Pty Limited | 33,333,333 | 2.51% |
| Umbiram Pty Ltd <Michael Hoy Superfund A/C> | 22,434,705 | 1.69% |
| Mrs Zi Juan QI <Chen Family A/C> | 20,000,000 | 1.51% |
| Standby Forty-Six Pty Limited | 20,000,000 | 1.51% |
| 3M Holdings Pty Limited <3M Investment Spec A/C> | 18,999,671 | 1.43% |
| Mr William John Dunn | 16,000,000 | 1.21% |
| Pathold No 222 Pty Ltd | 15,200,000 | 1.15% |
| Mrs Sharon Lewis | 14,977,737 | 1.13% |
| Dr Huy Tran | 13,254,912 | 1.00% |
| Citicorp Nominees Pty Limited | 11,835,825 | 0.89% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 11,723,262 | 0.88% |
| Hirsch Financial Pty Ltd | 11,565,387 | 0.87% |
| Mr Jiashun Yang | 11,367,587 | 0.86% |
| Mr Bryan Strode | 11,200,000 | 0.84% |
| Vicex Holdings Proprietary Limited <Vicex Superannuation A/C> | 11,200,000 | 0.84% |
| Fluhalp Pty Ltd <Fordholm A/C> | 11,000,000 | 0.83% |
| Dr Angela Fay Dulhunty | 10,000,000 | 0.75% |
| Mr Daniel Kochanowicz | 10,000,000 | 0.75% |
| Mr Dobrica Okulic | 10,000,000 | 0.75% |